Finerenone NDA Submitted for Diabetic Kidney Disease
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
Chronic Kidney Disease
Dapagliflozin Gets Breakthrough Therapy Status for CKD Indication
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
Tenapanor Under Review for Hyperphosphatemia in CKD
Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.
Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.
FDA Cites Deficiencies in Veverimer NDA for Metabolic Acidosis in CKD
Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.
Trial Investigating Dapagliflozin in CKD Meets All End Points
The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.
Finerenone Found to Delay Progression of Diabetic Kidney Disease
Early results from the phase 3 FIDELIO-DKD study also show that finerenone reduces the risk for a cardiovascular secondary endpoint in patients with diabetic kidney disease.
Adverse Drug Reactions Common in CKD
Nearly a third of serious adverse drug reactions in patients with chronic kidney disease may be preventable, according to investigators.
Allopurinol Does Not Affect eGFR in Chronic Kidney Disease
And, serum urate lowering with allopurinol did not affect GFR in T1DM and diabetic kidney disease.
Rituximab Superior for Preventing ANCA-Associated Vasculitis Relapse
Compared with azathioprine, rituximab decreased the risk of another relapse by 70% among patients who had experienced relapse and received re-induction of remission with rituximab, a study showed.
